U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07390552) titled 'A Phase 2 Study of PLH-2301 in Subjects With Sarcopenia' on Jan. 29.
Brief Summary: This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia.
Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks.
The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.
Study Start Date: Feb. 23
Study Type: INTERVENTIONAL
Condition:
Sarcopenia in Elderly
Intervention:
DRUG: PLH-2301
PLH-2301 administered o...